– “Late-breaking abstract” selected by the AASLD as one of the best of the 2022 edition (“Best of the Liver Meeting”)
– The phase II study of PXL065 for the treatment of NASH met its primary efficacy endpoint of reduction in liver fat mass at all doses and showed significant improvement in fibrosis, without worsening of NASH
– PXL065 is one of the most advanced treatments in development for NASH, a disease for which there is currently no approved treatment
LYON, France, November 7, 2022 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , announces today that the results of its phase II study (DESTINY-1) of PXL065 for the treatment of NASH have been presented during the “Late-breaking abstract” session of the Liver Meeting® 2022, organized by the American Association for the Study of Liver Diseases (AASLD), held in Washington, USA.
To receive information from POXEL in real time, send a request to [email protected].